Apogee Therapeutics Inc (APGE) Stock Price, Quote & News

Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical t...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 394 5230

Website: www.apogeetherapeutics.com

Address:

Building 17, Suite 102b 221 Crescent Street, Waltham, United States

BEATOFtheMARKET Oct. 24 at 10:24 PM

$AOA $AON $APA $APD $APGE 🔥

0 · Reply

JarvisFlow Oct. 21 at 12:43 PM

Mizuho has adjusted their stance on Apogee Therapeutics ( $APGE ), setting the rating to Outperform with a target price of 105.

0 · Reply

Rvazstocksfl Oct. 21 at 12:27 PM

$APGE wow 🤩

0 · Reply

Pika_Capital Oct. 14 at 2:44 PM

$ORKA $APGE $SYRE reminder

0 · Reply

Pika_Capital Oct. 14 at 1:21 AM

$SYRE I expect strong demand during offering as for $APGE Stock is green AH, tomorrow should be interesting

0 · Reply

Pika_Capital Oct. 11 at 12:02 PM

$PTGX proceeds will be redeployed into $IMVT, $APGE (possibly more $GMAB ) and across bunch of other names in pfolio. May reenter $BHVN again but not sure, it's a lower conviction name going into PDUFa.

2 · Reply

swampwiz0 Oct. 10 at 12:25 AM

$APGE CHA-CHING AGAIN!

0 · Reply

_CircuitBreaker Oct. 9 at 9:51 PM

Keep a close watch on CMCT! $APGE $BLBX $HTZ $CC !

0 · Reply

Quantumup Oct. 9 at 6:13 PM

BofA⬇️ $APGE's PT to $82 from $89 to reflect Wednesday's capital raise—made no changes to APG777 launch timing or PoS assumptions; Reiterated Buy. $REGN $SNY BofA said: Next catalysts in 1Q after development timeline updates APGE has narrowed guidance for the following APG777 (IL-13) readouts: 1) AD Ph 2 Part A 52-week maintenance readout now expected in 1Q26 (vs 1H-2026 previously), 2) asthma Ph 1b readout also now expected in 1Q26 (vs 1H-2026 previously), and 3) AD2 Part B 16-week readout now expected 2Q26 (vs mid-2026 previously). APGE still guides for 2029 launch. Other readouts are on track including APG279 (IL-13 + OX40Lcombination) Phlb proof of concept readout (vs. Dupixent) in AD (in 2H26) and APG777AD Ph 3 initiation (in 2H26).

0 · Reply